Rocket Pharmaceuticals’ (RCKT) Outperform Rating Reiterated at Wedbush
Wedbush reaffirmed their outperform rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a research report sent to investors on Friday,Benzinga reports. Wedbush currently has a $32.00 target price on the biotechnology company’s stock. A number of other research analysts have also commented on the company. Chardan Capital raised their price target on […]
Wedbush reaffirmed their outperform rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a research report sent to investors on Friday,Benzinga reports. Wedbush currently has a $32.00 target price on the biotechnology company’s stock. A number of other research analysts have also commented on the company. Chardan Capital raised their price target on […]
